HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

VitaPulse Blood Pressure, Cholesterol Testimonials Sputter In NAD Review

This article was originally published in The Rose Sheet

Executive Summary

NAD says Princeton Nutrients also now knows to include on its website all product reviews from customers for supplements rather than only positive reviews.

You may also be interested in...



FTC Updates Endorsement Guide Resource: 'What People Are Asking'

Agency's updated FAQ web page tackles questions stakeholders have been asking in recent years about its Endorsement Guide, including the appropriate way to provide disclosures on social-media platforms and the responsibilities of companies using large networks of bloggers and other influencers to promote products.

Firms Should Keep Claim-Substantiation Documents Ready For Review – FTC

A consent-order requirement that dietary supplement firms Martek and i-Health retain and make available for inspection all supporting documents for claims substantiation should be a best practice for consumer-product firms making health claims, an FTC lawyer suggests. The agency likely will dig deeper into underlying statistical analyses of studies than the peer-review panels of journals.

Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation

Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108706

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel